Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.

You may also be interested in...



Actavis’ MoxDuo: Can A Generic Firm Drive Growth With A Low-Dose Product?

Actavis aims to replace its Kadian pain franchise through a deal with QRxPharma for a fixed-dose combination of morphine and oxycodone.

Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse

The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.

Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse

The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel